Ornidyl, Vaniqa(eflornithine)
Iwilfin, Vaniqa (eflornithine) is a small molecule pharmaceutical. Eflornithine was first approved as Ornidyl on 1990-11-28. It is used to treat african trypanosomiasis, hypertrichosis, and protozoan infections in the USA. It has been approved in Europe to treat hirsutism. The pharmaceutical is active against ornithine decarboxylase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Iwilfin (discontinued: Ornidyl, Vaniqa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eflornithine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| IWILFIN | US WorldMeds | N-215500 RX | 2023-12-13 | 1 products, RLD, RS |
Show 2 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| african trypanosomiasis | — | D014353 | B56 |
| hypertrichosis | — | D006983 | L68 |
| protozoan infections | — | D011528 | B50-B64 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
EFLORNITHINE HYDROCHLORIDE, IWILFIN, USWM | |||
| 2030-12-13 | ODE-462 | ||
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX16: Eflornithine
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01C: Agents against leishmaniasis and trypanosomiasis
— P01CX: Other agents against leishmaniasis and trypanosomiasis in atc
— P01CX03: Eflornithine
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| African trypanosomiasis | D014353 | — | B56 | — | 2 | 4 | 1 | — | 5 |
| Hirsutism | D006628 | HP_0001007 | L68.0 | — | — | — | 2 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenomatous polyposis coli | D011125 | — | D13.91 | — | 1 | 2 | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | 1 | — | — | 2 |
| Precancerous conditions | D011230 | — | — | — | 1 | 1 | — | — | 2 |
| Astrocytoma | D001254 | EFO_0000271 | — | — | — | 1 | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 3 | 6 | — | — | 1 | 9 |
| Medulloblastoma | D008527 | — | — | — | 1 | — | — | 1 | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
| Adenomatous polyps | D018256 | — | D28 | — | 1 | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhabdoid tumor | D018335 | — | — | — | — | — | — | 1 | 1 |
| Primitive neuroectodermal tumors | D018242 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Eflornithine |
| INN | eflornithine |
| Description | Eflornithine is a fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2. It has a role as a trypanocidal drug. It is a fluoroamino acid and an alpha-amino acid. It is functionally related to an ornithine. |
| Classification | Small molecule |
| Drug class | Fc fusion protein |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCCC(N)(C(=O)O)C(F)F |
Identifiers
| PDB | — |
| CAS-ID | 70052-12-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL830 |
| ChEBI ID | 41948 |
| PubChem CID | 3009 |
| DrugBank | DB03856 |
| UNII ID | ZQN1G5V6SR (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Eflornithine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,315 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
370 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use